Bavarian Nordic Company Description
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.
It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Country | Denmark |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,605 |
| CEO | Paul Chaplin |
Contact Details
Address: Philip Heymans Alle 3 Hellerup, 2900 Denmark | |
| Phone | 45 33 26 83 83 |
| Website | bavarian-nordic.com |
Stock Details
| Ticker Symbol | BVNKF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0015998017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | Chief Executive Officer and President |
| Henrik Juuel M.Sc. | Chief Financial Officer and Executive Vice President |
| Russell Thirsk M.Sc. | Executive Vice President and Chief Operating Officer |
| Rolf Sass Sørensen | Vice President of Investor Relations and Communications |
| Jean-Christophe May M.B.A., Pharm.D. | Executive Vice President and Chief Commercial Officer |